In a recent study, combinatorial treatment of FAK inhibitor and erlotinib have shown synergistic effect in reducing cell viability in EGFR-TKI-resistant NSCLC cell lines [48]. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.